NCT04059224View on ClinicalTrials.gov

TraMel-WT: A Trial of Trametinib in Patients With Advanced Pretreated BRAFV600 Wild-type Melanoma

PHASE2CompletedINTERVENTIONAL
Enrollment

45

Participants

Timeline

Start Date

January 28, 2019

Primary Completion Date

June 30, 2023

Study Completion Date

June 30, 2023

Conditions
Stage IV MelanomaStage III Melanoma
Interventions
DRUG

Trametinib

Trametinib 2 mg once a day by mouth.

DRUG

Dabrafenib

Dabrafenib 50 mg twice a day by mouth. Dabrafenib can be uptitrated to 150 mg twice a day in case of dose-limiting trametinib-associated skin toxicity.

Trial Locations (1)

1090

Universitair Ziekenhuis Brussel, Jette

All Listed Sponsors
lead

Universitair Ziekenhuis Brussel

OTHER

NCT04059224 - TraMel-WT: A Trial of Trametinib in Patients With Advanced Pretreated BRAFV600 Wild-type Melanoma | Biotech Hunter | Biotech Hunter